A phase 2 trial of veliparib (ABT-888) and local exposure to radiation preceded by veliparib with TMZ as a maintenance therapy, in recently detected high-grade glioma patients without mutations in BRAFV600 and H3 K27M.A randomized trial of phase II/III using placebo or veliparib with TMZ (combination) in GBM patients who are newly diagnosed with hypermethylation of MGMT promoter. This evidence concerns the gene MGMT and central nervous system cancer.